new indications for glp-1 drugs What to know about the era of What's next for GLP-1 innovation:

Moreover, the reduced splanchnic blood flow could affect nutrient uptake or affect digestion (107) leads to uncertainty regarding effects on memory and cognitive functions

For example, naltrexone-bupropion is not suitable for patients with uncontrolled hypertension [62] and phentermine is contraindicated in patients with a history of cardiovascular disease [63]

doi: 10.1155/2009/101659 60 JiS.WangL.LiL

In a randomized, placebo-controlled trial of semaglutide treatment, 62 % of adolescent participants in the semaglutide group achieved a loss of body weight of at least 10 %, with 37 % of subjects achieving weight reduction of at least 20 % [138,156]

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor